This small cap biotech stock has major catalysts on the horizon

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses with Potentially ONE Drug ͏  ͏  ͏  ͏ ­ ­ ­ ­ Unsubscribe A Message from Smallcaps Daily This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses with Potentially ONE Drug The public company’s lead drug candidate NV-387, a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials. A broad-spectrum antiviral drug such as this one would be a highly desirable drug globally because it would enable treatment of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. What else does this? Antibiotics. The technology behind this could completely transform the way viruses and their variants are treated worldwide and there’s a good chance this public company holds the golden ticket. As biotech stages a big comeback, this is a company you’ll want to have on your radar. Click here to learn more about the incredible investment opportunity this organization may provide. Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.   This message is a paid advertisement sent on behalf of Smallcaps Daily, a third-party advertiser of DividendStocks.com and MarketBeat.     This message is a paid advertisement for NanoViricides, Inc. (NYSE American: NNVC) from Smallcaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $3,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Smallcaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc. (NYSE American: NNVC) on Interactive Offers' website for additional information about the relationship between Interactive Offers and NanoViricides, Inc. (NYSE American: NNVC) .     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Your 401K Won't Survive Kamala's Coup (Unless You Do THIS)